(Q39432616)

English

Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

object named as

David Roulois

1

0 references

Christophe Blanquart

object named as

Christophe Blanquart

2

0 references

Jean-Francois Fonteneau

object named as

Jean-François Fonteneau

6

0 references

author name string

Clarisse Panterne

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Fabien Gueugnon

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Marc Grégoire

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

13 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

European Journal of Immunology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

42

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

783-789

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

describes a project that uses

0 references

0 references

0 references

0 references

0 references

Asbestos and mesothelioma: worldwide trends

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Valproic acid for the treatment of myeloid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Decitabine and its role in the treatment of hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

MUC1 immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Mucins in cancer: function, prognosis and therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Human DF3/MUC1 carcinoma-associated protein functions as an oncogene

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Identification of novel markers for the diagnosis of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

21 January 2018

Malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141800

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/EJI.201141800

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39432616&oldid=1827574716"